Current Approaches to Transplantation for FLT3-ITD AML.

doi:10.1007/s11899-020-00558-5

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Current Approaches to Transplantation for FLT3-ITD AML.

Current hematologic malignancy reports - 1 Feb 2020

Hunter Bradley D, Chen Yi-Bin

Abstract excerpt

PURPOSE OF REVIEW: This review discusses the current standard of care for incorporation of FLT3 TKIs and HCT into the treatment of FLT3-ITD AML. Additionally, this review provides an approach to the patient with relapsed/refractory disease. RECENT FINDINGS: Over the last decade, the routine use of HCT as consolidative therapy and the development of FLT3 TKIs have significantly improved remission rates and overall...

Topics

Biomarkers, Tumor
Drug Resistance, Neoplasm
Genetic Predisposition to Disease
Hematopoietic Stem Cell Transplantation
Humans
Leukemia, Myeloid, Acute
Molecular Targeted Therapy
Mutation
Phenotype
Protein Kinase Inhibitors
Recurrence
Risk Assessment
Risk Factors
Transplantation, Homologous
Treatment Outcome
fms-Like Tyrosine Kinase 3

Source

Open in PubMed

Identifiers

PMID: 32034660
DOI: 10.1007/s11899-020-00558-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics